Monoclonal antibody ‘critical intervention’ for preventing infant RSV, study suggests Researchers found that nirsevimab reduced hospitalisations caused by respiratory syncytial virus in infants by more than 80%.…
Lost days: the unstemmed rise in mental health-related absences There has been a significant rise in sickness absence for mental health reasons among hospital pharmacists in England over the past five years. What needs to change and where can NHS pharmacists access help in the meantime?…
MHRA to review blood monitoring requirements for clozapine patients Starting in summer 2025, the Medicines and Healthcare products Regulatory Agency will seek views on ways to improve awareness of patient risks related to clozapine.…
Smoking cessation drug could help young people quit vaping, study results suggest Researchers found that varenicline is an effective vaping cessation drug among participants aged 16–25 years who vape nicotine daily or near daily.…
Neonatal sepsis: prevention and management The third article in a series on complications associated with prematurity and unwell neonates.…
NICE reverses draft guidance to recommend targeted therapy for patients with advanced bowel cancer The National Institute for Health and Care Excellence said the treatment should be available on the NHS after the manufacturer provided additional clinical evidence.…
Coroner writes to ICB following death of patient who took too many of their prescribed drugs The ‘Prevention of future deaths’ report, published on 16 April 2025, was issued following the death of patient who was waiting for mental health support.…
Government ends programme to tackle drug deaths and drug-related offending Between January 2021 and June 2024, Project ADDER benefited nearly 5,000 people in drug treatment and led to more than 39,000 arrest for drug offences.…
Antibiotic could help tackle drug-resistant gonorrhoea, study results suggest Researchers found that gepotidacin was as effective as the current recommended first-line therapy for gonorrhoea.…
NICE recommends cladribine for treating active relapsing forms of multiple sclerosis Cladribine (Mavenclad; Merck) is recommended for treating active relapsing-remitting multiple sclerosis in adults when high-efficacy disease-modifying therapies would be offered.…
